RT Journal Article SR Electronic T1 Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors mediating cytotoxicity of virus-infected target cells in non-severe COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.20.21260845 DO 10.1101/2021.07.20.21260845 A1 Karolin I. Wagner A1 Laura M. Mateyka A1 Sebastian Jarosch A1 Vincent Grass A1 Simone Weber A1 Kilian Schober A1 Monika Hammel A1 Teresa Burrell A1 Behnam Kalali A1 Holger Poppert A1 Henriette Beyer A1 Sophia Schambeck A1 Stefan Holdenrieder A1 Andrea Strötges-Achatz A1 Verena Haselmann A1 Michael Neumaier A1 Johanna Erber A1 Alina Priller A1 Sarah Yazici A1 Hedwig Roggendorf A1 Marcus Odendahl A1 Torsten Tonn A1 Andrea Dick A1 Klaus Witter A1 Hrvoje Mijočević A1 Ulrike Protzer A1 Percy A. Knolle A1 Andreas Pichlmair A1 Claudia S. Crowell A1 Markus Gerhard A1 Elvira D’Ippolito A1 Dirk H. Busch YR 2021 UL http://medrxiv.org/content/early/2021/07/23/2021.07.20.21260845.abstract AB T cell immunity is crucial for the control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and has been widely characterized on a quantitative level. In contrast, the quality of such T cell responses has been poorly investigated, in particular in the case of CD8+ T cells. Here, we explored the quality of SARS-CoV-2-specific CD8+ T cell responses in individuals who recovered from mild symptomatic infections, through which protective immunity should develop, by functional characterization of their T cell receptor (TCR) repertoire. CD8+ T cell responses specific for SARS-CoV-2-derived epitopes were low in frequency but could be detected robustly early as well as late - up to twelve months - after infection. A pool of immunodominant epitopes, which accurately identified previous SARS-CoV-2 infections, was used to isolate TCRs specific for epitopes restricted by common HLA class I molecules. TCR-engineered T cells showed heterogeneous functional avidity and cytotoxicity towards virus-infected target cells. High TCR functionality correlated with gene signatures of T cell function and activation that, remarkably, could be retrieved for each epitope:HLA combination and patient analyzed. Overall, our data demonstrate that highly functional HLA class I TCRs are recruited and maintained upon mild SARS-CoV-2 infection. Such validated epitopes and TCRs could become valuable tools for the development of diagnostic tests determining the quality of SARS-CoV-2-specific CD8+ T cell immunity, and thereby investigating correlates of protection, as well as to restore functional immunity through therapeutic transfer of TCR-engineered T cells.Competing Interest StatementD.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics/ Celgene) and T Cell Factory B.V. (now Kite/Gilead). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics, a Bristol Myers Squibb Company. The other authors have no financial conflicts of interest.Funding StatementThis study was supported by the EIT Health CoViproteHCt #20877, the German National Network of University Medicine of the Federal Ministry of Education and Research (BMBF; NaFoUniMedCovid19, 01KX2021; COVIM) and the DFG SFB1321 (Modeling and Targeting Pancreatic Cancer). E.D. was funded by the Corona-Forschungsantraege (Fakultaet f. Medizin). V.G. and A. Pichlmair. were funded by ERC consolidator grant (ERC-CoG ProDAP, 817798), the German Federal Ministry of Education and Research (COVINET), and the German Research Foundation (PI 1084/5 and TRR179, TRR237) to AP. L.M.M. was supported by a PhD fellowship from the Boehringer Ingelheim Fonds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: ethics committee of the Technical University of Munich (reference number 182/20) and the Institutional Ethics Committee of the University Medicine Mannheim (reference number 2020-556N)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript contains all relevant data; beyond the main figures supplemantary data have been added to the manuscript..